{"id":2685,"date":"2023-01-16T12:44:10","date_gmt":"2023-01-16T17:44:10","guid":{"rendered":"https:\/\/fifarma.org\/?post_type=publicaciones&p=2685"},"modified":"2025-06-18T15:59:12","modified_gmt":"2025-06-18T20:59:12","slug":"analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries","status":"publish","type":"publicaciones","link":"https:\/\/fifarma.org\/pt\/publicacoes\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/","title":{"rendered":"Analysis of access to innovative medicines in Chile compared to other OECD countries"},"content":{"rendered":"\n

This analysis seeks to compare the timing of reimbursement or coverage of innovative molecules between Chile and 22 other member countries of the OECD (Organization for Economic Cooperation and Development), and provides relevant elements that allow parametrizing the access dynamics of some prescription drugs in Chile<\/p>\n\n\n\n

Preview<\/a><\/div>\n\n\n
English<\/a><\/div>\n\n
2018<\/a><\/div>\n\n
Medicamentos Innovadores<\/a><\/div>\n
\n\n\t\t\n
    \n\t\t\t <\/ul>\n <\/div> \n","protected":false},"author":24,"parent":0,"template":"","ano":[43],"idioma":[45],"etiquetas-publicacion":[28],"categoria-publicacion":[35],"class_list":["post-2685","publicaciones","type-publicaciones","status-publish","hentry","ano-43","idioma-english","etiquetas-publicacion-medicamentos-innovadores","categoria-publicacion-articulo-academico"],"yoast_head":"\nAnalysis of access to innovative medicines in Chile compared to other OECD countries - FIFARMA<\/title>\n<meta name=\"description\" content=\"This analysis seeks to compare the timing of reimbursement or coverage of innovative molecules between Chile and 22 other member countries of the OECD (Organization for Economic Cooperation and Development), and provides relevant elements that allow parametrizing the access dynamics of some prescription drugs in Chile\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/pt\/publicacoes\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Analysis of access to innovative medicines in Chile compared to other OECD countries\" \/>\n<meta property=\"og:description\" content=\"This analysis seeks to compare the timing of reimbursement or coverage of innovative molecules between Chile and 22 other member countries of the OECD (Organization for Economic Cooperation and Development), and provides relevant elements that allow parametrizing the access dynamics of some prescription drugs in Chile\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/pt\/publicacoes\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-18T20:59:12+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\\\/\",\"name\":\"Analysis of access to innovative medicines in Chile compared to other OECD countries - FIFARMA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"datePublished\":\"2023-01-16T17:44:10+00:00\",\"dateModified\":\"2025-06-18T20:59:12+00:00\",\"description\":\"This analysis seeks to compare the timing of reimbursement or coverage of innovative molecules between Chile and 22 other member countries of the OECD (Organization for Economic Cooperation and Development), and provides relevant elements that allow parametrizing the access dynamics of some prescription drugs in Chile\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publicaciones\",\"item\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Analysis of access to innovative medicines in Chile compared to other OECD countries\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Analysis of access to innovative medicines in Chile compared to other OECD countries - FIFARMA","description":"This analysis seeks to compare the timing of reimbursement or coverage of innovative molecules between Chile and 22 other member countries of the OECD (Organization for Economic Cooperation and Development), and provides relevant elements that allow parametrizing the access dynamics of some prescription drugs in Chile","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/pt\/publicacoes\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/","og_locale":"pt_BR","og_type":"article","og_title":"Analysis of access to innovative medicines in Chile compared to other OECD countries","og_description":"This analysis seeks to compare the timing of reimbursement or coverage of innovative molecules between Chile and 22 other member countries of the OECD (Organization for Economic Cooperation and Development), and provides relevant elements that allow parametrizing the access dynamics of some prescription drugs in Chile","og_url":"https:\/\/fifarma.org\/pt\/publicacoes\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/","og_site_name":"FIFARMA","article_modified_time":"2025-06-18T20:59:12+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fifarma.org\/publicaciones\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/","url":"https:\/\/fifarma.org\/publicaciones\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/","name":"Analysis of access to innovative medicines in Chile compared to other OECD countries - FIFARMA","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"datePublished":"2023-01-16T17:44:10+00:00","dateModified":"2025-06-18T20:59:12+00:00","description":"This analysis seeks to compare the timing of reimbursement or coverage of innovative molecules between Chile and 22 other member countries of the OECD (Organization for Economic Cooperation and Development), and provides relevant elements that allow parametrizing the access dynamics of some prescription drugs in Chile","breadcrumb":{"@id":"https:\/\/fifarma.org\/publicaciones\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/publicaciones\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/publicaciones\/analysis-of-access-to-innovative-medicines-in-chile-compared-to-other-oecdcountries\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"Publicaciones","item":"https:\/\/fifarma.org\/publicaciones\/"},{"@type":"ListItem","position":3,"name":"Analysis of access to innovative medicines in Chile compared to other OECD countries"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/publicaciones\/2685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/publicaciones"}],"about":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/types\/publicaciones"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/users\/24"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/media?parent=2685"}],"wp:term":[{"taxonomy":"ano","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/ano?post=2685"},{"taxonomy":"idioma","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/idioma?post=2685"},{"taxonomy":"etiquetas-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/etiquetas-publicacion?post=2685"},{"taxonomy":"categoria-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/categoria-publicacion?post=2685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}